NCT06148402View on ClinicalTrials.gov

Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 8, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Unresectable/Metastatic Colorectal Cancer
Interventions
DRUG

Fruquintinib plus camrelizumab and capecitabine

fruquintinib 5 mg once daily, 2 weeks on/1 week off, plus camrelizumab 200 mg Q3W and capecitabine 750mg/square meter twice, 2 weeks on/1 week off, q3w

Trial Locations (1)

510000

RECRUITING

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER